Gossamer Bio (NASDAQ:GOSS) is a clinical-stage biopharmaceutical company headquartered in San Diego, California, with additional research and development operations in Cambridge, Massachusetts. Since its founding in 2015 by industry veteran Jack Lief, the company has been dedicated to discovering and developing novel therapies for patients suffering from immune-mediated diseases, gastrointestinal disorders, and oncology indications. Gossamer Bio’s approach emphasizes small molecules and antibodies designed to modulate key pathways in inflammation, fibrosis, and tumor growth.
At the core of Gossamer Bio’s pipeline are several product candidates in various stages of clinical development. Etrasimod, an oral selective sphingosine-1-phosphate receptor modulator, is under investigation for indications such as ulcerative colitis and Crohn’s disease. The company is also advancing GB1275, an oral CD11b modulator being evaluated in solid tumors to alter the tumor microenvironment and potentially enhance the activity of existing immunotherapies. Additional assets, including GB004 for inflammatory bowel disease and GB002 for pulmonary arterial hypertension, illustrate the company’s breadth across inflammatory and fibrotic disorders.
Gossamer Bio’s research efforts are bolstered by strategic collaborations and a global footprint of clinical trial sites spanning North America and Europe. The company maintains partnerships with academic centers and contract research organizations to accelerate the translation of preclinical findings into human studies. From its inception, Gossamer Bio has prioritized patient-focused development, incorporating translational biomarkers and imaging endpoints to better understand drug effects and optimize dosing strategies.
Leadership at Gossamer Bio comprises a team of seasoned executives and scientific experts. Founder and Chief Executive Officer Jack Lief brings decades of experience in life sciences leadership and clinical development. The senior management team includes specialists in immunology, molecular biology, and regulatory affairs who collectively guide the company’s strategic vision. As Gossamer Bio advances its pipeline toward potential regulatory submissions, its multidisciplinary team remains committed to delivering transformative treatments for complex diseases.
